CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
CASI Pharmaceuticals, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$0.10+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.6399 (−94.25%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
CASI Pharmaceuticals, Inc. saw revenue fall 27.4% to $20.71M over fiscal 2025. Free cash flow was -$20.77M.
Revenue
$20.71M
-27.4% vs. a year earlier
Operating income
-$45.01M
FY2025
Free cash flow
-$20.77M
FY2025
EPS, diluted
-$2.59
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $20.71M
- Net income
- -$48.06M
- EPS, diluted
- -$2.59
- Free cash flow
- -$20.77M
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
$20.71M-27.4% YoY
Gross profit
$10.08M-9.6% YoY
Operating income
-$45.01M
Net income
-$48.06M
EPS, diluted
-$2.59
Free cash flow
-$20.77M
Reported period